RPTX
Repare Therapeutics Inc.
A clinical-stage biotech company that designs targeted cancer drugs using a "synthetic lethality" approach — hunting the specific genetic weaknesses of tumor cells so treatments can kill cancer while sparing healthy tissue. Founded in 2016 by three cell-biology researchers in Montreal, the company's name is a play on "repair" and "pare," nodding to the DNA-repair pathways it exploits and the way it pares away cancer cells. Its experimental therapies include lunresertib and camonsertib, developed for cancers with certain DNA-repair defects.
CUSIP: 760273102HealthcareCA2 holders
Recent Activity
2025Q2
2 sells
-1.94M shares
-1.94M shares
-1.12M shares
ARK InvestEXIT
-1.12M shares
2025Q1
2 sells
-493.3K shares(-20.3%)
-493.3K shares(-20.3%)
-875.5K shares(-43.8%)
ARK InvestTRIM
-875.5K shares(-43.8%)
Loading more activity...